Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
Xiaoyan LuJames JarrettSusannah SadlerMin TanJames DennisVipul JairathPublished in: International journal of clinical pharmacy (2022)
The current treatment landscape benefits patients with moderately to severely active UC, improving key outcomes; filgotinib 200 mg was similar to current standard of care in most outcomes.